2006
Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer
Abu-Khalaf MM, Juneja V, Chung GG, DiGiovanna MP, Sipples R, McGurk M, Zelterman D, Haffty B, Reiss M, Wackers FJ, Lee FA, Burtness BA. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Research And Treatment 2006, 104: 341-349. PMID: 17051423, DOI: 10.1007/s10549-006-9413-7.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionEnd of chemotherapyEquilibrium radionuclide angiographyBreast cancerAdjuvant therapySequential doxorubicinCardiac functionIpsilateral axillary lymph nodesHigh-risk breast cancerRisk breast cancerClinical heart failureInitiation of chemotherapyAxillary lymph nodesVentricular ejection fractionEnd of therapyLong-term cardiotoxicityMedian absolute changeEligible patientsFilgrastim supportLate cardiotoxicityAxillary nodesAsymptomatic declineEjection fractionHeart failureLymph nodes
2005
Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer
Abu-Khalaf MM, Windsor S, Ebisu K, Salikooti S, Ananthanarayanan G, Chung GG, DiGiovanna MP, Haffty BG, Abrams M, Farber LR, Hsu AD, Reiss M, Zelterman D, Burtness BA. Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer. Oncology 2005, 69: 372-383. PMID: 16319508, DOI: 10.1159/000089991.Peer-Reviewed Original ResearchConceptsHigh-risk breast cancerBreast cancerAdjuvant therapyLymph nodesCommon grade 3 toxicitiesIpsilateral axillary lymph nodesGrade 3 toxicityGrade 3/4 neutropeniaPhase II studyAxillary lymph nodesPalmar-plantar erythrodysesthesiaDose-denseEligible patientsFeasible regimenFilgrastim supportNeutropenic feverDistant diseaseAxillary nodesDose intensityII studyBC surgerySequential doxorubicinAcute leukemiaMetastatic cancerMedian number
1999
Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting.
Burtness B, Windsor S, Holston B, DiStasio S, Staugaard-Hahn C, Abrantes J, Kneuper-Hall R, Farber L, Orell J, Bober-Sorcinelli K, Haffty BG, Reiss M. Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting. The Cancer Journal 1999, 5: 224-9. PMID: 10439168.Peer-Reviewed Original ResearchConceptsBreast cancerDefinitive breast cancer surgeryMetastatic axillary lymph nodesHigh-risk breast cancerMore axillary nodesMyalgia/arthralgiaGrade 3 toxicityNausea/vomitingPercent of patientsAxillary lymph nodesHigh-risk patientsBreast cancer surgeryPreliminary efficacy dataFilgrastim supportNeutropenic feverAcceptable toxicityAdjuvant therapyAxillary nodesDose intensityStandard therapyBone scanLymph nodesCancer surgeryDistant metastasisAcute leukemia